ZA200806542B - Hla-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same - Google Patents

Hla-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Info

Publication number
ZA200806542B
ZA200806542B ZA200806542A ZA200806542A ZA200806542B ZA 200806542 B ZA200806542 B ZA 200806542B ZA 200806542 A ZA200806542 A ZA 200806542A ZA 200806542 A ZA200806542 A ZA 200806542A ZA 200806542 B ZA200806542 B ZA 200806542B
Authority
ZA
South Africa
Prior art keywords
hla
peptide
restricted
same
pharmaceutical composition
Prior art date
Application number
ZA200806542A
Other languages
English (en)
Inventor
Sugiyama Haruo
Original Assignee
Int Inst Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Int Inst Cancer Immunology Inc filed Critical Int Inst Cancer Immunology Inc
Publication of ZA200806542B publication Critical patent/ZA200806542B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
ZA200806542A 2006-02-22 2008-07-28 Hla-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same ZA200806542B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006045287 2006-02-22

Publications (1)

Publication Number Publication Date
ZA200806542B true ZA200806542B (en) 2009-07-29

Family

ID=38437397

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806542A ZA200806542B (en) 2006-02-22 2008-07-28 Hla-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same

Country Status (23)

Country Link
US (5) US8759483B2 (ru)
EP (3) EP1988163B1 (ru)
JP (1) JP5393144B2 (ru)
KR (1) KR101391561B1 (ru)
CN (3) CN102250211A (ru)
AU (1) AU2007218649B2 (ru)
BR (1) BRPI0708125A2 (ru)
CA (4) CA2886551A1 (ru)
CY (1) CY1113117T1 (ru)
DK (2) DK2518149T3 (ru)
ES (3) ES2558330T3 (ru)
HK (1) HK1125968A1 (ru)
IL (4) IL193026A (ru)
MX (1) MX2008010842A (ru)
MY (1) MY149527A (ru)
NO (1) NO20084008L (ru)
PH (1) PH12012502372A1 (ru)
PL (1) PL1988163T3 (ru)
PT (1) PT1988163E (ru)
RU (2) RU2435782C2 (ru)
SI (1) SI1988163T1 (ru)
WO (1) WO2007097358A1 (ru)
ZA (1) ZA200806542B (ru)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
ES2558330T3 (es) 2006-02-22 2016-02-03 International Institute Of Cancer Immunology, Inc. Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
CA2645766A1 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and methods of use thereof
CN104774910B (zh) 2007-02-27 2018-04-10 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
MY170306A (en) 2010-10-05 2019-07-17 Int Inst Cancer Immunology Inc Method for activating helper t cell
KR20140033029A (ko) * 2011-04-01 2014-03-17 메모리얼 슬로안-케터링 캔서 센터 에이치엘에이 에이2에 의해 제공된 더블유티1 펩타이드에 특이적인 티 세포 수용체 유사 항체
JP6122779B2 (ja) * 2011-09-14 2017-04-26 株式会社癌免疫研究所 抗ｗｔ１抗体の測定方法
CN104684577B (zh) 2012-01-13 2018-05-08 纪念斯隆凯特林癌症中心 免疫原性wt-1肽及其使用方法
CN104797711B (zh) 2012-09-12 2018-09-21 株式会社癌免疫研究所 抗原特异性辅助性t细胞受体基因
SI2931304T1 (sl) 2012-12-13 2021-11-30 The Trustees Of The University Of Pennsylvania Cepivo proti WT1
MX2015007745A (es) 2012-12-17 2015-12-15 Otsuka Pharma Co Ltd Metodo para activar la celula t auxiliar.
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
JP6512567B2 (ja) 2013-02-05 2019-05-15 日東電工株式会社 経皮投与用ｗｔ１ペプチド癌ワクチン組成物
KR20140100417A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
KR102050931B1 (ko) 2013-02-05 2019-12-02 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 테이프제
RU2014102941A (ru) 2013-02-05 2015-08-10 Нитто Денко Корпорейшн Вакцинная композиция для введения через слизистую оболочку
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
IN2014CH00395A (ru) 2013-02-05 2015-04-03 Nitto Denko Corp
KR20140100419A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
IN2014CH00396A (ru) 2013-02-05 2015-04-03 Nitto Denko Corp
AU2015362379B2 (en) 2014-12-11 2020-05-14 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
CA2974066A1 (en) 2014-12-25 2016-06-30 International Institute Of Cancer Immunology, Inc. Method for modifying t cell population
KR20170132202A (ko) 2015-03-20 2017-12-01 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Isg15 및 어쥬번트로써의 이의 용도
DK3539974T5 (en) 2016-11-09 2024-05-27 Osaka Univ Method for modifying t cell population

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0453560B1 (en) 1989-11-13 1999-05-26 Massachusetts Institute Of Technology Localization and characterization of the wilms' tumor gene
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US6270777B1 (en) 1996-12-20 2001-08-07 University Technologies International Inc. Conserved metalloprotease epitopes
GB9805877D0 (en) * 1998-03-20 1998-05-13 Imp Cancer Res Tech Cancer
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
MXPA01003344A (es) 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US6797695B1 (en) * 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
WO2002014361A2 (en) * 2000-08-17 2002-02-21 Agensys, Inc. NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
KR100863853B1 (ko) * 2001-03-22 2008-10-15 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 더블유티1 개변 펩티드
US20040197892A1 (en) * 2001-04-04 2004-10-07 Michael Moore Composition binding polypeptides
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
CA2489227C (en) 2002-06-12 2012-03-13 Chugai Seiyaku Kabushiki Kaisha Hla-a24-restricted cancer antigen peptides
JP4611022B2 (ja) * 2002-09-12 2011-01-12 株式会社癌免疫研究所 癌抗原ペプチド製剤
KR20120054644A (ko) 2003-01-15 2012-05-30 추가이 세이야쿠 가부시키가이샤 이량체화 펩티드
CA2514058C (en) * 2003-01-24 2014-05-13 Agensys, Inc. Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
US6980709B2 (en) 2003-06-20 2005-12-27 Northrop Grumman Corporation Polymeric material with voids that compress to allow the polymeric material to absorb applied force and decrease reaction force to one or more sensor fibers
DK2186896T3 (en) 2004-03-31 2015-12-21 Int Inst Cancer Immunology Inc Cancer antigen peptides derived from WT1
ES2558330T3 (es) 2006-02-22 2016-02-03 International Institute Of Cancer Immunology, Inc. Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo

Also Published As

Publication number Publication date
HK1125968A1 (ru) 2009-08-21
DK2518149T3 (en) 2016-01-11
US8933038B2 (en) 2015-01-13
CN102702319A (zh) 2012-10-03
CN102250211A (zh) 2011-11-23
EP1988163B1 (en) 2012-06-27
SI1988163T1 (sl) 2012-09-28
PT1988163E (pt) 2012-08-28
BRPI0708125A2 (pt) 2011-05-17
AU2007218649B2 (en) 2013-01-10
ES2387685T3 (es) 2012-09-28
EP2518149A1 (en) 2012-10-31
CA2886552A1 (en) 2007-08-30
DK1988163T3 (da) 2012-08-20
EP2385117A1 (en) 2011-11-09
CY1113117T1 (el) 2016-04-13
US20140193442A1 (en) 2014-07-10
US8968745B2 (en) 2015-03-03
NO20084008L (no) 2008-11-24
IL193026A (en) 2015-09-24
MY149527A (en) 2013-09-13
CN102702319B (zh) 2015-01-28
CN101384716B (zh) 2013-03-13
EP1988163A4 (en) 2010-03-17
PL1988163T3 (pl) 2012-11-30
EP2518149B1 (en) 2015-12-16
CA2638122A1 (en) 2007-08-30
US20140193443A1 (en) 2014-07-10
KR20080097203A (ko) 2008-11-04
US20120195918A1 (en) 2012-08-02
IL232408A0 (en) 2014-06-30
IL232409A0 (en) 2014-06-30
CN101384716A (zh) 2009-03-11
MX2008010842A (es) 2008-09-01
PH12012502372B1 (en) 2016-04-04
JPWO2007097358A1 (ja) 2009-07-16
WO2007097358A1 (ja) 2007-08-30
CA2886551A1 (en) 2007-08-30
AU2007218649A1 (en) 2007-08-30
IL218172A0 (en) 2012-03-29
US8945578B2 (en) 2015-02-03
IL193026A0 (en) 2009-02-11
US20140199332A1 (en) 2014-07-17
ES2558330T3 (es) 2016-02-03
KR101391561B1 (ko) 2014-05-02
US8759483B2 (en) 2014-06-24
ES2587980T3 (es) 2016-10-28
RU2011132212A (ru) 2013-02-10
JP5393144B2 (ja) 2014-01-22
CA2886615A1 (en) 2007-08-30
PH12012502372A1 (en) 2016-04-04
US8778350B2 (en) 2014-07-15
US20100292160A1 (en) 2010-11-18
RU2008137635A (ru) 2010-03-27
RU2435782C2 (ru) 2011-12-10
EP2385117B1 (en) 2016-07-27
EP1988163A1 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
IL232408A0 (en) 3303 * a-hla – reduced 1wt peptide and pharmaceutical compound containing it
IL215334A0 (en) Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
IL197923A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
IL197924A (en) Synthetic peptides, pharmaceutical preparations containing them and their uses
EP2056835A4 (en) PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
HK1141312A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same cdca1
IL194429A0 (en) Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
IL186959A0 (en) Peptides and pharmaceutical compositions containing the same
AP2009004960A0 (en) Co-crystals and pharmaceutical compositions comprising the same
HK1244819A1 (zh) Foxm1肽和包含foxm1肽的藥劑
EP1890677A4 (en) PHARMACEUTICAL COMPOSITIONS AND THEIR USE
IL193211A (en) Derivatives of Indzol-Troaril and pharmaceutical preparations containing them
IL203986A0 (en) Cdh3 peptide and medicinal agent comprising the same
GB0610090D0 (en) Particulate drug compositions and their uses
GB0604187D0 (en) Peptide and uses thereof
GB0614365D0 (en) Pharmaceutical compositions and their use
IL192824A (en) Peptide compounds, pharmaceuticals containing them and their use
GB0701295D0 (en) Z-stilbenes derivatives and the pharmaceutical composition thereof
GB0724523D0 (en) Pharmaceutical compositions comprising clotrimazole or analogs thereof and their use